You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameReboxetine
Accession NumberDB00234  (APRD00198)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionReboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DavedaxNot Available
EdronaxNot Available
NoreboxNot Available
ProliftNot Available
SolvexNot Available
VestraNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Reboxetine mesilate
98769-84-7
Thumb
  • InChI Key: CGTZMJIMMUNLQD-STYNFMPRSA-N
  • Monoisotopic Mass: 409.155908767
  • Average Mass: 409.5
DBSALT000890
Categories
UNII947S0YZ36I
CAS number71620-89-8
WeightAverage: 313.397
Monoisotopic: 313.167793605
Chemical FormulaC19H23NO3
InChI KeyCBQGYUDMJHNJBX-RTBURBONSA-N
InChI
InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1
IUPAC Name
(2R)-2-[(R)-(2-ethoxyphenoxy)(phenyl)methyl]morpholine
SMILES
[H][C@@](OC1=CC=CC=C1OCC)(C1=CC=CC=C1)[C@@]1([H])CNCCO1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassPhenol ethers
Sub ClassNot Available
Direct ParentPhenol ethers
Alternative Parents
Substituents
  • Phenoxy compound
  • Phenol ether
  • Alkyl aryl ether
  • Aralkylamine
  • Monocyclic benzene moiety
  • Morpholine
  • Oxazinane
  • Dialkyl ether
  • Secondary aliphatic amine
  • Ether
  • Oxacycle
  • Azacycle
  • Secondary amine
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organooxygen compound
  • Organic oxygen compound
  • Organic nitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of clinical depression.
PharmacodynamicsReboxetine is a selective noradrenaline reuptake inhibitor (NaRI), the first drug of new antidepressant class. Reboxetine is an a-ariloxybenzyl derivative of morpholine. Reboxetine is primarily used to treat depression but has also been found useful in the treatment of narcolepsy and panic disorders.
Mechanism of actionReboxetine is a selective inhibitor of noradrenaline reuptake. It inhibits noradrenaline reuptake in vitro to a similar extent to the tricyclic antidepressant desmethylimipramine. Reboxetine does not affect dopamine or serotonin reuptake and it has low in vivo and in vitro affinity for adrenergic, cholinergic, histaminergic, dopaminergic and serotonergic receptors.
Related Articles
AbsorptionReboxetine is rapidly and extensively absorbed following oral administration.
Volume of distributionNot Available
Protein binding98%
Metabolism

Reboxetine is metabolized by dealkylation, hydroxylation and oxidation followed by glucuronide or sulphate conjugation. It is metabolized by the cytochrome P450 CYP isoenzyme 3A4.

Route of eliminationNot Available
Half life12.5 hours
ClearanceNot Available
ToxicityReports of seizures (rare) have been reported
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier+0.9381
Caco-2 permeable+0.575
P-glycoprotein substrateSubstrate0.7914
P-glycoprotein inhibitor IInhibitor0.8825
P-glycoprotein inhibitor IINon-inhibitor0.5968
Renal organic cation transporterNon-inhibitor0.5581
CYP450 2C9 substrateNon-substrate0.8237
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5402
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.8063
CYP450 2D6 inhibitorNon-inhibitor0.5687
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.6318
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5218
Ames testNon AMES toxic0.9141
CarcinogenicityNon-carcinogens0.9083
BiodegradationNot ready biodegradable0.9372
Rat acute toxicity2.0972 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7754
hERG inhibition (predictor II)Inhibitor0.717
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point170-171 °C (Mesylate salt)Not Available
water solubility8 mg/mL (Mesylate salt)Not Available
logP3.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0223 mg/mLALOGPS
logP3.06ALOGPS
logP3.28ChemAxon
logS-4.2ALOGPS
pKa (Strongest Basic)7.91ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area39.72 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity89.48 m3·mol-1ChemAxon
Polarizability34.51 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Fleishaker JC: Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000 Dec;39(6):413-27. [PubMed:11192474 ]
  2. Edwards DM, Pellizzoni C, Breuel HP, Berardi A, Castelli MG, Frigerio E, Poggesi I, Rocchetti M, Dubini A, Strolin Benedetti M: Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos. 1995 Aug;16(6):443-60. [PubMed:7579027 ]
  3. Wienkers LC, Allievi C, Hauer MJ, Wynalda MA: Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1334-40. [PubMed:10534319 ]
  4. Kasper S, el Giamal N, Hilger E: Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82. [PubMed:11249515 ]
External Links
ATC CodesN06AX18
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Reboxetine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Reboxetine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Reboxetine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Reboxetine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Reboxetine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Reboxetine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Reboxetine.
AmiodaroneThe metabolism of Reboxetine can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Reboxetine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Reboxetine.
AprepitantThe serum concentration of Reboxetine can be increased when it is combined with Aprepitant.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Reboxetine.
AtazanavirThe metabolism of Reboxetine can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Reboxetine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Reboxetine.
AtomoxetineThe metabolism of Reboxetine can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Reboxetine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Reboxetine.
BexaroteneThe serum concentration of Reboxetine can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Reboxetine can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Reboxetine.
BortezomibThe metabolism of Reboxetine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Reboxetine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Reboxetine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Reboxetine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Reboxetine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Reboxetine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Reboxetine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Reboxetine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Reboxetine.
CarbamazepineThe metabolism of Reboxetine can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Reboxetine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Reboxetine.
CeritinibThe serum concentration of Reboxetine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Reboxetine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Reboxetine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Reboxetine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Reboxetine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Reboxetine.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Reboxetine.
ClarithromycinThe metabolism of Reboxetine can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Reboxetine.
ClemastineThe metabolism of Reboxetine can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Reboxetine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Reboxetine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Reboxetine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Reboxetine.
ClotrimazoleThe metabolism of Reboxetine can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Reboxetine.
CobicistatThe metabolism of Reboxetine can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Reboxetine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Reboxetine.
ConivaptanThe serum concentration of Reboxetine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Reboxetine.
CrizotinibThe metabolism of Reboxetine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Reboxetine.
CyclosporineThe metabolism of Reboxetine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Reboxetine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Reboxetine.
DabrafenibThe serum concentration of Reboxetine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Reboxetine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Reboxetine.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Reboxetine.
DarunavirThe metabolism of Reboxetine can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Reboxetine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Reboxetine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Reboxetine.
DeferasiroxThe serum concentration of Reboxetine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Reboxetine can be decreased when combined with Delavirdine.
DexamethasoneThe serum concentration of Reboxetine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Reboxetine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Reboxetine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Reboxetine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Reboxetine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Reboxetine.
DihydroergotamineThe metabolism of Reboxetine can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Reboxetine.
DiltiazemThe metabolism of Reboxetine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Reboxetine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Reboxetine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Reboxetine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Reboxetine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Reboxetine.
DoxycyclineThe metabolism of Reboxetine can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Reboxetine can be decreased when combined with Dronedarone.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Reboxetine.
EfavirenzThe serum concentration of Reboxetine can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Reboxetine.
EnzalutamideThe serum concentration of Reboxetine can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Reboxetine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Reboxetine.
ErythromycinThe metabolism of Reboxetine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Reboxetine.
Eslicarbazepine acetateThe serum concentration of Reboxetine can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Reboxetine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Reboxetine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Reboxetine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Reboxetine.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Reboxetine.
EtravirineThe serum concentration of Reboxetine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Reboxetine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Reboxetine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Reboxetine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Reboxetine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Reboxetine.
FluconazoleThe metabolism of Reboxetine can be decreased when combined with Fluconazole.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Reboxetine.
FluvoxamineThe metabolism of Reboxetine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Reboxetine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Reboxetine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Reboxetine can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Reboxetine can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Reboxetine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Reboxetine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Reboxetine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Reboxetine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Reboxetine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Reboxetine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Reboxetine.
IdelalisibThe serum concentration of Reboxetine can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Reboxetine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Reboxetine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Reboxetine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Reboxetine.
IndinavirThe metabolism of Reboxetine can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Reboxetine.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Reboxetine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Reboxetine.
IsavuconazoniumThe metabolism of Reboxetine can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Reboxetine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Reboxetine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Reboxetine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Reboxetine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Reboxetine.
KetoconazoleThe metabolism of Reboxetine can be decreased when combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Reboxetine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Reboxetine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Reboxetine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Reboxetine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Reboxetine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Reboxetine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Reboxetine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Reboxetine.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Reboxetine.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Reboxetine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Reboxetine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Reboxetine.
LopinavirThe metabolism of Reboxetine can be decreased when combined with Lopinavir.
LosartanThe serum concentration of Losartan can be increased when it is combined with Reboxetine.
LovastatinThe metabolism of Reboxetine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Reboxetine can be increased when it is combined with Luliconazole.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Reboxetine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Reboxetine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Reboxetine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Reboxetine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Reboxetine.
MifepristoneThe metabolism of Reboxetine can be decreased when combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Reboxetine.
MitotaneThe serum concentration of Reboxetine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Reboxetine.
ModafinilThe serum concentration of Reboxetine can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Morphine can be increased when it is combined with Reboxetine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Reboxetine.
NadololThe serum concentration of Nadolol can be increased when it is combined with Reboxetine.
NafcillinThe serum concentration of Reboxetine can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Reboxetine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Reboxetine.
NefazodoneThe metabolism of Reboxetine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Reboxetine can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Reboxetine.
NetupitantThe serum concentration of Reboxetine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Reboxetine can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Reboxetine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Reboxetine.
NilotinibThe metabolism of Reboxetine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Reboxetine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Reboxetine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Reboxetine.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Reboxetine.
OlaparibThe metabolism of Reboxetine can be decreased when combined with Olaparib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Reboxetine.
OsimertinibThe serum concentration of Reboxetine can be increased when it is combined with Osimertinib.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Reboxetine.
PalbociclibThe serum concentration of Reboxetine can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Reboxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Reboxetine.
PentobarbitalThe metabolism of Reboxetine can be increased when combined with Pentobarbital.
PhenobarbitalThe metabolism of Reboxetine can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Reboxetine.
PhenytoinThe metabolism of Reboxetine can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Reboxetine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Reboxetine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Reboxetine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Reboxetine.
PosaconazoleThe metabolism of Reboxetine can be decreased when combined with Posaconazole.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Reboxetine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Reboxetine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Reboxetine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Reboxetine.
PrimidoneThe metabolism of Reboxetine can be increased when combined with Primidone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Reboxetine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Reboxetine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Reboxetine.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Reboxetine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Reboxetine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Reboxetine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Reboxetine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Reboxetine.
RanolazineThe metabolism of Reboxetine can be decreased when combined with Ranolazine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Reboxetine.
RifabutinThe metabolism of Reboxetine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Reboxetine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Reboxetine.
RifapentineThe metabolism of Reboxetine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Reboxetine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Reboxetine.
RitonavirThe metabolism of Reboxetine can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Reboxetine.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Reboxetine.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Reboxetine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Reboxetine.
SaquinavirThe metabolism of Reboxetine can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Reboxetine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Reboxetine.
SildenafilThe metabolism of Reboxetine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Reboxetine.
SiltuximabThe serum concentration of Reboxetine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Reboxetine can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Reboxetine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Reboxetine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Reboxetine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Reboxetine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Reboxetine.
St. John's WortThe serum concentration of Reboxetine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Reboxetine can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Reboxetine can be decreased when combined with Sulfisoxazole.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Reboxetine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Reboxetine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Reboxetine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Reboxetine.
TelaprevirThe metabolism of Reboxetine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Reboxetine.
TelithromycinThe metabolism of Reboxetine can be decreased when combined with Telithromycin.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Reboxetine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Reboxetine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Reboxetine.
TiclopidineThe metabolism of Reboxetine can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Reboxetine.
TocilizumabThe serum concentration of Reboxetine can be decreased when it is combined with Tocilizumab.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Reboxetine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Reboxetine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Reboxetine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Reboxetine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Reboxetine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Reboxetine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Reboxetine.
VenlafaxineThe metabolism of Reboxetine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Reboxetine.
VerapamilThe metabolism of Reboxetine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Reboxetine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Reboxetine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Reboxetine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Reboxetine.
VoriconazoleThe metabolism of Reboxetine can be decreased when combined with Voriconazole.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Reboxetine.
ZiprasidoneThe metabolism of Reboxetine can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Rauhut AS, Mullins SN, Dwoskin LP, Bardo MT: Reboxetine: attenuation of intravenous nicotine self-administration in rats. J Pharmacol Exp Ther. 2002 Nov;303(2):664-72. [PubMed:12388649 ]
  2. Wilson AA, Johnson DP, Mozley D, Hussey D, Ginovart N, Nobrega J, Garcia A, Meyer J, Houle S: Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol. 2003 Feb;30(2):85-92. [PubMed:12623106 ]
  3. Lin KS, Ding YS, Kim SW, Kil KE: Synthesis, enantiomeric resolution, F-18 labeling and biodistribution of reboxetine analogs: promising radioligands for imaging the norepinephrine transporter with positron emission tomography. Nucl Med Biol. 2005 May;32(4):415-22. [PubMed:15878511 ]
  4. Spivak B, Strous RD, Shaked G, Shabash E, Kotler M, Weizman A: Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. J Clin Psychopharmacol. 2006 Apr;26(2):152-6. [PubMed:16633143 ]
  5. Mitchell HA, Ahern TH, Liles LC, Javors MA, Weinshenker D: The effects of norepinephrine transporter inactivation on locomotor activity in mice. Biol Psychiatry. 2006 Nov 15;60(10):1046-52. Epub 2006 Aug 7. [PubMed:16893531 ]
  6. Kasper S, el Giamal N, Hilger E: Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82. [PubMed:11249515 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23